These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 21492782

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. The effect of PPAR-gamma agonist on (18)F-FDG uptake in tumor and macrophages and tumor cells.
    Kim SL, Kim EM, Cheong SJ, Lee CM, Kim DW, Jeong HJ, Lim ST, Sohn MH, Yim CY.
    Nucl Med Biol; 2009 May; 36(4):427-33. PubMed ID: 19423011
    [Abstract] [Full Text] [Related]

  • 24. In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography.
    Nielsen CH, Jensen MM, Kristensen LK, Dahlman A, Fröhlich C, Jacobsen HJ, Poulsen TT, Lantto J, Horak ID, Kragh M, Kjaer A.
    Oncotarget; 2015 Nov 10; 6(35):37486-99. PubMed ID: 26460961
    [Abstract] [Full Text] [Related]

  • 25. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture.
    Aloj L, Caracó C, Jagoda E, Eckelman WC, Neumann RD.
    Cancer Res; 1999 Sep 15; 59(18):4709-14. PubMed ID: 10493529
    [Abstract] [Full Text] [Related]

  • 26. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS.
    Mol Pharmacol; 2006 Nov 15; 70(5):1534-41. PubMed ID: 16887935
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells.
    Xu H, Yu Y, Marciniak D, Rishi AK, Sarkar FH, Kucuk O, Majumdar AP.
    Mol Cancer Ther; 2005 Mar 15; 4(3):435-42. PubMed ID: 15767552
    [Abstract] [Full Text] [Related]

  • 30. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C, Duan X, Xu L, Ye J, Zhao J, Liu Y.
    Breast Cancer Res Treat; 2012 Dec 15; 136(3):739-48. PubMed ID: 23117856
    [Abstract] [Full Text] [Related]

  • 31. Comparisons of [18F]-1-deoxy-1-fluoro-scyllo-inositol with [18F]-FDG for PET imaging of inflammation, breast and brain cancer xenografts in athymic mice.
    McLarty K, Moran MD, Scollard DA, Chan C, Sabha N, Mukherjee J, Guha A, McLaurin J, Nitz M, Houle S, Wilson AA, Reilly RM, Vasdev N.
    Nucl Med Biol; 2011 Oct 15; 38(7):953-9. PubMed ID: 21982567
    [Abstract] [Full Text] [Related]

  • 32. Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab.
    Costantini DL, Villani DF, Vallis KA, Reilly RM.
    J Nucl Med; 2010 Mar 15; 51(3):477-83. PubMed ID: 20150272
    [Abstract] [Full Text] [Related]

  • 33. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.
    Costantini DL, Chan C, Cai Z, Vallis KA, Reilly RM.
    J Nucl Med; 2007 Aug 15; 48(8):1357-68. PubMed ID: 17631548
    [Abstract] [Full Text] [Related]

  • 34. Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model.
    Pastuskovas CV, Mundo EE, Williams SP, Nayak TK, Ho J, Ulufatu S, Clark S, Ross S, Cheng E, Parsons-Reponte K, Cain G, Van Hoy M, Majidy N, Bheddah S, dela Cruz Chuh J, Kozak KR, Lewin-Koh N, Nauka P, Bumbaca D, Sliwkowski M, Tibbitts J, Theil FP, Fielder PJ, Khawli LA, Boswell CA.
    Mol Cancer Ther; 2012 Mar 15; 11(3):752-62. PubMed ID: 22222630
    [Abstract] [Full Text] [Related]

  • 35. Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).
    Lin NU, Guo H, Yap JT, Mayer IA, Falkson CI, Hobday TJ, Dees EC, Richardson AL, Nanda R, Rimawi MF, Ryabin N, Najita JS, Barry WT, Arteaga CL, Wolff AC, Krop IE, Winer EP, Van den Abbeele AD.
    J Clin Oncol; 2015 Aug 20; 33(24):2623-31. PubMed ID: 26169615
    [Abstract] [Full Text] [Related]

  • 36. Expression and function of hexose transporters GLUT1, GLUT2, and GLUT5 in breast cancer-effects of hypoxia.
    Hamann I, Krys D, Glubrecht D, Bouvet V, Marshall A, Vos L, Mackey JR, Wuest M, Wuest F.
    FASEB J; 2018 Sep 20; 32(9):5104-5118. PubMed ID: 29913554
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance (111)In-DTPA-hEGF Auger electron radiation therapy.
    Cornelissen B, Darbar S, Hernandez R, Kersemans V, Tullis I, Barber PR, Smart S, Vojnovic B, Reilly R, Vallis KA.
    J Nucl Med; 2011 May 20; 52(5):776-83. PubMed ID: 21498540
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.